NRx Pharmaceuticals (NRXP) - NOV 10 is the GDUFA date! Yesterday they announced receipt of a letter from the FDA stating that only a product labeling correction is needed. Great news! NRXP is on track for approval and their drug is now as highly derisked as you can get.
NRXP is set to receive FDA approval by Nov 10 with only minor labeling corrections needed. The company will launch the only preservative-free, US-manufactured ketamine (KETAFREE) into a $3B market facing supply shortages, with 4-5M vials ready to ship immediately and capacity for 1M vials/month. High short interest and recent price decline create a potential squeeze setup.
At post $2.60·Now $2.74+5.4% since postedas of Oct 13, 12:31 PM ET
1d—
3d+1.2%
1w—
1m—
3m—
6m—
1y—
CYCURION (CYCU) - This data clearly indicates the substantial risk being taken by those betting against this company that continues to announce wins and is UNDERVALUED. Next week is shaping up to have great potential!
CYCU is undervalued and has announced multiple notable wins recently. High short-sale volume (reaching 62%) suggests shorts are taking substantial risk, creating potential catalyst for share price recovery next week.
At post $3.54·Now $2.18-38.4% since postedas of Oct 19, 4:30 PM ET
1d—
3d—
1w-5.9%
1m+7.9%
3m—
6m—
1y—
NRx Pharmaceuticals (NRXP) - Two September Catalysts Upon Us
NRx Pharmaceuticals has two major catalysts expected by end-2026: ANDA approval for preservative-free IV ketamine (anytime through Sep 2026) and NDA submission for NRX-100 (psychiatric indication). The company has exclusive market access, domestic supply, and 1M vial/month production capacity. Analyst price targets range $25-$45, with near-term price support of $10-12 on ANDA approval alone.
At post $3.44·Now $2.74-20.4% since postedas of Oct 13, 12:31 PM ET
1d+0.6%
3d+1.5%
1w+0.9%
1m-17.2%
3m—
6m—
1y—
$CYCUr/pennystocksGeneral Discussionbullish u/stockratic · 54d ago10 prior · 50% at 3mo Cycurion (CYCU) - 1:8 Reverse Split Just Announced - Looks like a DFNS type setup <FOR YOUR WATCH LIST>
CYCU's 1:8 reverse split effective August 28 is expected to catalyze a post-split melt-up similar to the DFNS setup, driven by strong fundamentals including a $54.6M contract, $30M annualized revenue run-rate after the Digital Ally acquisition, and a $34M sales pipeline. Share price should trade well above the mechanical $3.52 post-split level as the market recognizes the company's improved competitive position and growth trajectory.
At post $3.67·Now $2.18-40.6% since postedas of Oct 19, 4:30 PM ET
1d+5.4%
3d+4.8%
1w-17.5%
1m-23.5%
3m—
6m—
1y—
NRx Pharmaceuticals (NRXP) - Awaiting ANDA (generic drug) approval for no-preservative Intravenous (IV) ketamine for analgesia (pain control) and anesthesia ... which will happen in the near term.
NRx Pharmaceuticals is positioned for near-term FDA approval of KETAFREE (preservative-free ketamine), addressing critical supply chain and safety issues while solving strategic FDA goals. The company has resolved the only outstanding FDA concern (luer lock vial attestation) and has significant pre-launch commercialization momentum, with share price expected to respond positively to ANDA approval and subsequent NDA filings.
At post $3.56·Now $2.74-23.0% since postedas of Oct 13, 12:31 PM ET
1d—
3d-3.1%
1w-0.3%
1m-6.7%
3m—
6m—
1y—
NRx Pharmaceuticals (NRXP) - Imminent Catalyst - 8-K dropped today (follow-up to yesterday's post - I encourage you to check it out). The stock is up nicely this morning, as a result! One of my favorite companies to hold. This company is a winner ... now ... and longer term.
NRx's KETAFREE ANDA is near approval with only a manufacturing certification hurdle remaining; the FDA has committed to expedited review due to ketamine shortage and first commercial sales are expected in 2026. The company is well-capitalized and positioned to supply preservative-free ketamine to a market currently facing supply constraints.
At post $3.58·Now $2.74-23.5% since postedas of Oct 13, 12:31 PM ET
1d—
3d-6.4%
1w-8.7%
1m-2.5%
3m—
6m—
1y—
NRX Pharmaceuticals (NRXP) - Imminent Catalyst and other statuses! This company is on the move and gaining traction. Price targets are multiples of the current share price.
NRX Pharmaceuticals has multiple imminent catalysts: KETAFREE (preservative-free IV ketamine) FDA ANDA decision expected imminently following no major deficiencies, NRX-100 NDA submission in final stages, and NRX-101 (combination therapy) in pivotal trials with BTD status. The company has built manufacturing capacity, raised capital, and positioned itself in a large market for depression and PTSD treatment, with price targets noted as multiples of current share price.
At post $3.09·Now $2.74-11.3% since postedas of Oct 13, 12:31 PM ET
1d+15.9%
3d+15.9%
1w+8.1%
1m+12.9%
3m—
6m—
1y—
(CYCU) Cycurion, Inc. Closes Acquisition of Digital Ally Video Solutions Business, Expanding Its Resources While Adding More Than $5 Million in Revenue and Over $1.2 Million in EBITDA — Bringing Annual Revenue Run Rate to Approximately $30 Million
Cycurion closed an acquisition adding $5M+ revenue and $1.2M EBITDA, bringing annual run rate to ~$30M. Combined with a recent $54M 10-year contract, the author values the company at ~$3/share based on 1x revenue multiple, implying upside from current levels.
At post $6.64·Now $2.18-67.2% since postedas of Oct 19, 4:30 PM ET
1d-6.5%
3d-26.4%
1w-29.2%
1m-45.9%
3m—
6m—
1y—
“Invested at $0.307, holding for 10x return”
Cycurion (CYCU)
Cybersecurity company with pending lawsuit against market makers alleging manipulation, projected $30M revenue by end 2026, new acquisition with 65-70% margins, and expected profitability by Q1 2027. Author expects 5-10x returns as fundamentals improve, with stock currently undervalued relative to revenue projections and comparable OTC growth stocks.
At post $2.48·Now $2.18-12.1% since postedas of Oct 19, 4:30 PM ET
1d+15.8%
3d+3.2%
1w-12.9%
1m+111.0%
3m—
6m—
1y—
Datavault (DVLT) gets $150M investment from Scilex Holdings (SCLX) -- sometimes you just get lucky on timing - (also below is the link to my DVLT post from 7 days ago)! GO!!!
Datavault (DVLT) received a $150M strategic investment from Scilex Holdings (SCLX), a significant capital injection that validates the company and should drive upside momentum.
At post $0.83·Now $0.13-83.9% since postedas of Oct 19, 4:30 PM ET
1d+31.3%
3d+31.3%
1w+84.3%
1m+312.0%
3m-3.6%
6m-24.1%
1y-81.9%
Long 25,000 shares of DVLT
Datavault AI (DVLT) launching leading tech - Sept 8 and Sept 9 PRs have the key info and as already posted, a CEO-affiliated company just acquired 10M shares at $.32 ($3.2M)
Datavault AI is launching proprietary wireless audio technology (WiSA E Endeavour) that outperforms Bluetooth with volume production beginning this quarter. The company's 72+ patent portfolio, recent $3.2M CEO-affiliated investment, and upcoming licensing partnerships provide catalysts for growth, though a delisting deadline in November creates near-term risk.
At post $0.41·Now $0.13-67.4% since postedas of Oct 19, 4:30 PM ET
1d+9.8%
3d+9.8%
1w+102.4%
1m+336.6%
3m+217.1%
6m+90.2%
1y-62.5%